Jennewein Biotechnologie

Nachrichtenüberblick und Pressemitteilungen


29.08.2011 Jennewein Biotechnologie and Pfizer Nutrition Collaborate on Human Milk Oligosaccharides

Jennewein Biotechnologie and Pfizer Nutrition Collaborate on Human Milk Components

Jennewein Biotechnologie today announced that the company has signed a license agreement with Pfizer Nutrition to develop and market two Human Milk Oligosaccharides (HMOs).

Human Milk Oligosaccharides represent a major component of mother’s milk, and provide short and long-term benefits to infants from birth onwards. Scientific research has shown that HMOs can significantly lower infants’ risk of infection during the time of lactation. In addition, these compounds are known to influence colonization of beneficial bacteria and support healthy immune development.